San Francisco venture capital firm Breakout Ventures announced the close of a $114 million fund to support founder-led companies working at the nexus of science and artificial intelligence. | San ...

Uğur Şahin, M.D., who is currently the CEO of BioNTech, and his wife Özlem Türeci, M.D., who is chief medical officer, founded mRNA-focused BioNTech in 2008. The company rose to prominence and ...

Vertex reported a phase 3 win for its kidney disease prospect povetacicept, meeting analyst expectations and firing the starting gun on a race to the FDA that could result in an accelerated approval ...

Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more ...

Bristol Myers Squibb’s mezigdomide has scored its first phase 3 win, with the Cereblon E3 ligase modulator (CELMoD) tied to a statistically significant improvement in progression-free survival (PFS) ...

AbbVie has unveiled the first data from its $350 million obesity bet, with the amylin analog demonstrating weight loss of close to 10% after 12 weeks in one dose cohort. Amylin emerged last year as ...

Regeneron’s Chinese partner reported Zepbound-like efficacy in a phase 3 trial, de-risking one part of the Big Biotech’s differentiated play for the obesity market.

Shanghai-based Tenacia Biotechnology is making a $308 million biobucks move for Rapport Therapeutics' leading asset focused on focal onset seizures (FOS) and primary generalized tonic-clonic seizures, ...

Researchers have shown that a standard mammogram can be capable of uncovering not just breast cancer, but a woman’s risk of heart disease as well, by using artificial intelligence to help | Using AI ...

LifeVac has picked up a groundbreaking clearance from the FDA for its suction-powered device designed to dislodge an object blocking a person’s airway, for use when other choking rescue p | With a ...

Pfizer is ramping up plans for tilrekimig after a phase 2 win raised hopes that the once-monthly trispecific antibody could hold its own against approved eczema drugs. | Pfizer is ramping up plans for ...

Italian pharma Alfasigma is handing $300 million to GSK for an itching treatment the FDA coul | Italian pharma Alfasigma is handing $300 million to GSK for an itching treatment the FDA could approve ...